📰 Not Estimable News

Not Estimable News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Not Estimable. Real-time updates on events, politics, business and more.

TALVEY▼ (talquetamab), is approved for the treatment of relapsed multiple myeloma

October 14, 2023

Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that

United States Thorsten Giesecke Patrick Hayden European Haematology Association Janssen Pharmaceutical Companies Of Johnson Drug Administration

Source: imt.ie

Johnson & Johnson : Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

June 5, 2023

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel... | June 5, 2023

United States Arnob Banerjee Satu Glawe Christie Corbett Yael Cohen European Commission

Source: marketscreener.com

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

June 3, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

United States Christie Corbett Arnob Banerjee Yael Cohen Satu Glawe Early Development Oncology

Source: prnewswire.com

Janssen Presents First Results from Dual Bispecific

June 3, 2023

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson &amp; Johnson announced today the first results from...

United States Region Flamande Edmond Chan Yael Cohen Arnob Banerjee Companies Of Johnson

Source: globenewswire.com

Daiichi Sankyo: Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer

June 3, 2022

Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort

United States Masashi Kawase Iane Krop Daiichi Sankyo Daiichi Sankyo Europe Gmb Patritumab Deruxtecan

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation